IP Library › Granted Patent US 12,735,678
Granted Patent B2
US 12,735,678 · App. 18/744,550 · Granted Sep 15, 2026

Compositions and methods for hematopoietic stem cell transplants

Inventors: Ivan Dimov (Menlo Park, CA); Nathaniel Fernhoff (Menlo Park, CA); Kevin Sheehan (Menlo Park, CA)
Assignee: Orca Biosystems, Inc.
C12N5/0637A61K40/10A61K40/11A61K40/22A61K40/418A61P3/00A61P7/06A61P21/00A61P35/02A61P37/02C12N5/0087C12N5/0636C12N5/0638C12N5/0646C12N5/0647A61K2239/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,678
App. No.
18/744,550
Granted
Sep 15, 2026
Kind
B2
Abstract

The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional αβ-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.

Claims (30)

1 . A method of treating a human subject in need thereof, the method comprising administering to the human subject a pharmaceutical composition comprising one or more unit doses of a cellular graft,

wherein each unit dose of the cellular graft comprises populations of therapeutic cells for each kilogram (kg) of body weight of a subject receiving the cellular graft, and

wherein the populations of therapeutic cells of each unit dose comprise:

more than 3×10 5 hematopoietic stem/progenitor cells (HSPC) per kilogram of body weight of the subject receiving the cellular graft,

more than 3×10 5 memory T cells (Tmem) per kilogram of body weight of the subject receiving the cellular graft,

more than 5×10 5 regulatory T cells (Treg) per kilogram of body weight of the subject receiving the cellular graft, and

less than 3×10 5 naïve conventional αβ-T cells per kilogram of body weight of the subject receiving the cellular graft.

2 . The method of claim 1 , wherein

the HSPC are CD34 + ,

the Tmem are CD3 + CD45RA − CD45RO + ,

the Treg are CD4 + CD25 + CD127 −/lo , CD45RA + , or a combination thereof, and

the naïve conventional αβ-T cells are CD3 + CD45RA + CD25 − TCR Va24Ja18 − .

3 . The method of claim 1 , wherein the populations of therapeutic cells of each unit dose comprises 1.0×10 6 to 50×10 6 HSPC per kilogram of body weight of the subject receiving the cellular graft.

4 . The method of claim 1 , wherein the populations of therapeutic cells of each unit dose comprises 0.3×10 6 to 1000×10 6 Tmem per kilogram of body weight of the subject receiving the cellular graft.

5 . The method of claim 1 , wherein the populations of therapeutic cells of each unit dose comprises 0.5×10 6 to 1000×10 6 Treg per kilogram of body weight of the subject receiving the cellular graft.

6 . The method of claim 1 , wherein the unit dose further comprises iNKT cells, and

wherein the populations of therapeutic cells of each unit dose comprise 0.5×10 3 to 2000×10 3 iNKT per kilogram of body weight of the subject receiving the cellular graft.

7 . The method of claim 6 , wherein the iNKT are CD3 + Vα24Jα18 + .

8 . The method of claim 1 , wherein the populations of therapeutic cells of each unit dose comprises 0.2×10 6 to 500×10 6 naïve Treg cells per kilogram of body weight of the subject receiving the cellular graft.

9 . The method of claim 1 , wherein the populations of therapeutic cells of each unit dose comprises less than 1×10 5 naïve conventional αβ-T cells per kilogram of body weight of the subject receiving the cellular graft.

10 . The method of claim 1 , wherein the pharmaceutical composition further comprises an excipient, and the excipient comprises one or more of Normosol-R and human serum.

11 . The method of claim 1 , wherein the human subject has or is suspected of having disease or disorder selected from the group consisting of: a leukemia, a lymphoma, a chronic infection, an autoimmune disease, a malignant or non-malignant blood disease, AML, ALL, CML, CLL, Multiple Myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, MDS, Lymphoproliferative diseases, type 1 diabetes, inborn errors of metabolism, genetic disease, sickle cell anemia, beta-thallasemia, multiple sclerosis, solid organ transplantation, Krohn's disease, ulcerative colitis, lupus, Hemophagocytic lymphohistiocytosis, glycogen storage disorders, mucopolysaccharidosis, and any other disease that would benefit from a HSPC transplant.

12 . The method of claim 1 , wherein each therapeutic cell population is administered to the subject as an individual pharmaceutical composition.

13 . The method of claim 1 , wherein the therapeutic cell populations are administered to the subject as a single pharmaceutical composition.

14 . The method of claim 1 , wherein one or more of the HSPC, Tmem, Treg, and naïve conventional αβ-T cells are isolated from a donor that is an HLA matched sibling donor, an HLA matched unrelated donor, a partially matched unrelated donor, a haploidentical donor, an autologous donor, an HLA unmatched donor, a pool of donors, or any combination thereof, relative to the human subject.

15 . The method of claim 1 , wherein one or more of the HSPC, Tmem, Treg, and naïve conventional αβ-T cells are haploidentical to the human subject.

16 . The method of claim 1 , wherein one or more of the HSPC, Tmem, Treg, and naïve conventional αβ-T cells are allogeneic or autologous relative to the human subject.

17 . The method of claim 1 , wherein one or more of the HSPC, Tmem, Treg, and naïve conventional αβ-T cells are isolated from mobilized peripheral blood, mobilized apheresis product, bone marrow, umbilical cord blood, non-mobilized blood, non-mobilized apheresis product, derived from one or more tissue harvests, or any combination thereof.

18 . The method of claim 1 , wherein the populations of therapeutic cells comprise HSPC provided by at least a first donor, and Treg and Tmem provided by at least a second donor.

19 . The method of claim 18 , wherein the first donor, the second donor, or both the first donor and second donor, is an HLA matched sibling donor, an HLA matched or partially matched unrelated donor, or haploidentical to the human subject.

Assignments (1)
SECURITY INTEREST Recorded Mar 2, 2026
From: ORCA BIOSYSTEMS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 073939/0071 →
Continuity (5)
Division 17091363 · Nov 6, 2020
Division 16388095 · Apr 18, 2019
Continuation 15922709 · Mar 15, 2018
Provisional Application 62471769 · Mar 15, 2017
Related Publication 20250019656A1 · Jan 16, 2025
References Cited (199)
US 5514340A · Lansdorp et al. · 1996 [cited by applicant]
US 5858358A · June et al. · 1999 [cited by applicant]
US 5928639A · Slavin · 1999 [cited by applicant]
US 6537807B1 · Smith et al. · 2003 [cited by applicant]
US 6544506B2 · Reisner · 2003 [cited by applicant]
US 7651855B2 · Blazar et al. · 2010 [cited by applicant]
US 8277811B2 · Zeng · 2012 [cited by applicant]
US 8632768B2 · Ildstad et al. · 2014 [cited by applicant]
US 8926964B2 · Hariri et al. · 2015 [cited by applicant]
US 8951793B2 · Tran et al. · 2015 [cited by applicant]
US 9156912B2 · Matsushima et al. · 2015 [cited by applicant]
US 9452184B2 · Ildstad et al. · 2016 [cited by applicant]
US 9523076B2 · Schoenbrunn et al. · 2016 [cited by applicant]
US 9738872B2 · Reisner et al. · 2017 [cited by applicant]
US 9795604B2 · Byrd et al. · 2017 [cited by applicant]
US 9896659B2 · Perry et al. · 2018 [cited by applicant]
US 10300090B2 · Dimov et al. · 2019 [cited by applicant]
US 10434121B2 · Reisner et al. · 2019 [cited by applicant]
US 10660954B2 · Mitchell et al. · 2020 [cited by applicant]
US 10806773B2 · Koreth et al. · 2020 [cited by applicant]
US 10842821B2 · Deitcher · 2020 [cited by applicant]
US 10857183B2 · Dimov et al. · 2020 [cited by applicant]
US 10881692B2 · Deitcher · 2021 [cited by applicant]
US 20020127208A1 · Waller et al. · 2002 [cited by applicant]
US 20030147865A1 · Salomon et al. · 2003 [cited by applicant]
US 20030223998A1 · Lamb et al. · 2003 [cited by applicant]
US 20040137617A1 · Luxembourg et al. · 2004 [cited by applicant]
US 20040228845A1 · Ildstad · 2004 [cited by applicant]
US 20050118142A1 · Ildstad · 2005 [cited by applicant]
US 20050214265A1 · Ildstad · 2005 [cited by applicant]
US 20060018885A1 · Ildstad · 2006 [cited by applicant]
US 20060222633A1 · Shlomchik et al. · 2006 [cited by applicant]
US 20070237752A1 · Christensen et al. · 2007 [cited by applicant]
US 20080032401A1 · Edinger et al. · 2008 [cited by applicant]
US 20080038231A1 · Rodgerson et al. · 2008 [cited by applicant]
US 20080095749A1 · Aggarwal et al. · 2008 [cited by applicant]
US 20080292601A1 · Song · 2008 [cited by applicant]
US 20090130067A1 · Buscher et al. · 2009 [cited by applicant]
US 20090297471A1 · Markovic et al. · 2009 [cited by applicant]
US 20100111905A1 · Balber · 2010 [cited by applicant]
US 20110059050A1 · Cetrulo et al. · 2011 [cited by applicant]
US 20110110909A1 · Ildstad et al. · 2011 [cited by applicant]
US 20110298883A1 · Ohyama · 2011 [cited by applicant]
US 20120177621A1 · Strober et al. · 2012 [cited by applicant]
US 20120269774A1 · Ichim et al. · 2012 [cited by applicant]
US 20140011690A1 · Dimov et al. · 2014 [cited by applicant]
US 20140212398A1 · Reisner et al. · 2014 [cited by applicant]
US 20140308250A1 · Handgretinger et al. · 2014 [cited by applicant]
US 20140369974A1 · Reisner et al. · 2014 [cited by applicant]
US 20150004176A1 · Garcia Santana · 2015 [cited by applicant]
US 20160040123A1 · Kanemura et al. · 2016 [cited by applicant]
US 20160166613A1 · Spencer et al. · 2016 [cited by applicant]
US 20160175358A1 · Jakobovits et al. · 2016 [cited by applicant]
US 20160184367A1 · Sackstein · 2016 [cited by applicant]
US 20160185861A1 · Bedoya et al. · 2016 [cited by applicant]
US 20160245805A1 · Baer et al. · 2016 [cited by applicant]
US 20160279171A1 · Gurney et al. · 2016 [cited by applicant]
US 20170121684A1 · Zuniga-Pflucker et al. · 2017 [cited by applicant]
US 20170216417A1 · Cohen et al. · 2017 [cited by applicant]
US 20170246277A1 · Schneck et al. · 2017 [cited by applicant]
US 20170296588A1 · Ichim et al. · 2017 [cited by applicant]
US 20180153145A1 · Gilson et al. · 2018 [cited by applicant]
US 20180161370A1 · Faustman · 2018 [cited by applicant]
US 20180251731A1 · Guillonneau et al. · 2018 [cited by applicant]
US 20180264039A1 · Dimov et al. · 2018 [cited by applicant]
US 20190032013A1 · Leventhal · 2019 [cited by applicant]
US 20190125795A1 · Rosen et al. · 2019 [cited by applicant]
US 20190183930A1 · Lamb et al. · 2019 [cited by applicant]
US 20190275079A1 · Ildstad et al. · 2019 [cited by applicant]
US 20190275085A1 · Deitcher et al. · 2019 [cited by applicant]
US 20190282618A1 · Rosen et al. · 2019 [cited by applicant]
US 20200016198A1 · Jongen et al. · 2020 [cited by applicant]
US 20200030380A1 · Ichim · 2020 [cited by applicant]
US 20200077644A1 · Church et al. · 2020 [cited by applicant]
US 20200150108A1 · Hill et al. · 2020 [cited by applicant]
US 20200179931A1 · Foster et al. · 2020 [cited by applicant]
US 20210008200A1 · Mitchell et al. · 2021 [cited by applicant]
US 20250019656A1 · Dimov et al. · 2025 [cited by applicant]
CA 2850961A1 · 2013 [cited by applicant]
EP 1185867A2 · 2002 [cited by applicant]
EP 2259065A1 · 2010 [cited by applicant]
EP 2352816B1 · 2015 [cited by applicant]
EP 2606120B1 · 2015 [cited by applicant]
EP 3037522A1 · 2016 [cited by applicant]
EP 3097917A1 · 2016 [cited by applicant]
EP 2558857B1 · 2017 [cited by applicant]
EP 3240803A2 · 2017 [cited by applicant]
EP 3340997A1 · 2018 [cited by applicant]
EP 2797421B1 · 2020 [cited by applicant]
EP 3676614A1 · 2020 [cited by applicant]
WO WO02098601A1 · 2002 [cited by applicant]
WO WO2004018996A2 · 2004 [cited by applicant]
WO 2007014420A1 · 2007 [cited by applicant]
WO WO2013008479A1 · 2013 [cited by applicant]
WO WO2013161257A1 · 2013 [cited by applicant]
WO WO2014015312A1 · 2014 [cited by applicant]
WO WO2015028750A1 · 2015 [cited by applicant]
WO WO2015127190A1 · 2015 [cited by applicant]
WO WO2015112793A3 · 2015 [cited by applicant]
WO WO2016013672A1 · 2016 [cited by applicant]
WO WO2016133907A1 · 2016 [cited by applicant]
WO 2016179684A1 · 2016 [cited by applicant]
WO WO2016179283A1 · 2016 [cited by applicant]
WO WO2017011804A1 · 2017 [cited by applicant]
WO WO2017023753A1 · 2017 [cited by applicant]
WO WO2017035375A1 · 2017 [cited by applicant]
WO WO2017042170A1 · 2017 [cited by applicant]
WO WO2017048809A1 · 2017 [cited by applicant]
WO WO2017078807A1 · 2017 [cited by applicant]
WO WO2017094008A1 · 2017 [cited by applicant]
WO WO2017096347A1 · 2017 [cited by applicant]
WO WO2017127755A1 · 2017 [cited by applicant]
WO WO2017132446A1 · 2017 [cited by applicant]
WO WO2017156365A1 · 2017 [cited by applicant]
WO WO2018013993A1 · 2018 [cited by applicant]
WO WO2018053485A1 · 2018 [cited by applicant]
WO WO2018170335A1 · 2018 [cited by applicant]
WO 2019108900A1 · 2019 [cited by applicant]
WO 2019157158A2 · 2019 [cited by applicant]
WO WO2020247341A1 · 2020 [cited by applicant]
WO 2021168376A1 · 2021 [cited by applicant]
WO 2022098926A1 · 2022 [cited by applicant]
WO 2023081320A1 · 2023 [cited by applicant]
Schaap, N. et al., “A Randomized Trial Comparing CD34 Enriched Grafts Versus CD3/CD19 Depleted Grafts in Partial T-cell Depleted Allogeneic Stem Cell Transplantation,” Bone Marrow Transplantation, vol. 45, No. Suppl. 2,… [cited by applicant]
Ayello, Janet et al., “Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapi… [cited by applicant]
Waller, Edmund K. et al., “Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naive T-Cells from Unrelated Donor Marrow Grafts: Results from BMTCTN 0201,” Journal of Clinical Oncology, vol. … [cited by applicant]
Laberko, Alexandria et al., “Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-[alpha]/[beta]- and CD19-Depleted Grafts,” Biology of Blood and M… [cited by applicant]
Srour, et al., Orca Q Demonstrates Favorable GvHD and Relapse Free Survival in Haploidentical Transplants without Post Transplant Cyclophosphamide, Orcabio, Jan. 14, 2023, publication downloaded from here: https://orcab… [cited by applicant]
Walker et al., De nova generation of antigen-specific co4+co2s+ regulatory T cells from human CD4 +co2s-cells, PNAS, vol. 102, No. 11, 4103-4108 (2005) www.pnas.org/cgi/doi/10.1073/pnas.0407691102. [cited by applicant]
Gattinoni et al., A human memory T cell subset with stem cell-like properties, Nature Medicine, vol. 17, No. 10 (2011) doi: 10.1038/nm.2446. [cited by applicant]
Valverde-Villegas et al., New Insights about Treg and Th17 Cells in HIV Infection and Disease Progression, Journal of Immunology Research, vol. 2015, Article ID 647916, 14 pages (2015) http://dx.doi.org/10.1155/2015/647… [cited by applicant]
Favaloro et al., Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state, Leukemia & Lymphoma, 55(5), (2014) 1090-1098, DOI: 10.3109/10428194.2013.825905. [cited by applicant]
Choi et al., Current and emerging strategies for the prevention of graft-versus-host disease, Nature Reviews Clinical Oncology, vol. 11, 536-547 (2014); doi: 10.1038/nrclinonc.2014.102. [cited by applicant]
Rowe, R Grant et al., “Engineering Hematopoietic Stem Cells: Lessons from Development,” Cell Stem Cell, vol. 18, No. 6, Jun. 2, 2016, pp. 707-720, XP029567594, ISSN: 1934-5909, DOI: 10.1016/J.STEM.2016.05.016. [cited by applicant]
Teschner, D. et al., “Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approch for GVHD prophylaxis,” Bone Marrow Transplantation, vol. 49, No. 1, Aug. 12, 2013, pp. 138-144, ISSN: 0268-3369,… [cited by applicant]
Handgretinger et al. (Curr Opin Hematol 2012, 19:434-439, DOI: 10.1097/MOH.0b013e3283582340) (Year: 2012). [cited by applicant]
U.S. Appl. No. 15/922,709 Notice of Allowance dated Jan. 8, 2019. [cited by applicant]
Anderson, et al., “Memory CD4+ T cells do not induce graft-versus-host disease,” The Journal of Clinical Investigation 112(1):101-108,2003. [cited by applicant]
Bleakley et al., “Engineering Human Peripheral Blood Stem Cell Grafts that are Depleted of Naive T Cells and Retain Functional Pathogen-Specific Memory T Cells,” Biol Blood Marrow Transplant 20:705-716. 2014. [cited by applicant]
Bleakley et al., Naive T Cell Depletion to Prevent Graft-Versus-Host Disease. National Institutes of Health. 2015. Fiscal Year 2014. [cited by applicant]
Bleakley et al., Naive T Cell Depletion to Prevent Graft-Verus-Host Disease. National Institutes of Health. 2015 Fiscal Year 2015. [cited by applicant]
Bleakley et al., Native T Cell Depletion to Prevent Graft-Versus-Host Disease. National Institutes of Health. 2015. Fiscal Year 2016. [cited by applicant]
Bleakley et al., Naive T Cell Depletion to Prevent Graft-Versus-Host Disease. National Institute of Health. 2015. Fiscal Year 2017. [cited by applicant]
Bleakley et al., “Outcomes of Acute Leukemia Patients Transplanted with Naive T Cell-Depleted Stem Cell Grafts,” The Journal of Clinical Investigation 125(7):2677-2689,2015. [cited by applicant]
Chaidos et al., “Graft Invariant Natural Killer T-Cell Dose Predicts Risk of Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation,” Blood 119(21):5030-5036, 2012. [cited by applicant]
Chen et al., “High-throughput Analysis and Protein Engineering Using Microcapillary Arrays,” Nature Chemical Biology 12:76-81, 2016. Published Dec. 7, 2015. (9 pages). [cited by applicant]
Cozzo et al., “Cutting Edge: Self-Peptides Drive the Peripheral Expansion of CD4+CD25+Regulatory T Cells,” The Journal of Immunology 171:5678-5682, 2003. (6 pages). [cited by applicant]
U.S. Appl. No. 15/922,709 Pre-Interview Office Action dated Sep. 13, 2018. [cited by applicant]
Shields et al., “Microfl. cell sorting: a rev. of adv. in separation of cells from debulking for rare cell isol.” Lab Chip. The Royal Soc. of Chem. 2015, 15, pp. 1230-1249. (Year: 2015). [cited by applicant]
Exley et al., “Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial,” American Association for Cancer Research, downloaded from http://clincancerres.aacrjournals.org … [cited by applicant]
Golubovskaya et al., “Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy,” Cancers Aug. 2016, 36;doi:10.3390/cancers8030036. [cited by applicant]
Hoffman et al., “Donor-type CD4+CD25+Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation,” Journal of Experimental Medicine 196(3):389-399, 2002. [cited by applicant]
Ianni et al., “Immunoselection and Clinical Use of T Regulatory Cells in HLA-haploidentical Stem Cell Transplantation,” Best Practice & Research Clinical Haematology 24:459-466, 2011. [cited by applicant]
Ianni et al., “Tregs Prevent GVHD and Promote Immune Reconstitution in HLA-haploidentical Transplantation,” Blood 117(14):3921-3928, 2011. (9 pages). [cited by applicant]
Keever-Taylor et al., Characteristics of CliniMACS® System CD34-Enriched T Cell-Depletd Grafts in a Multi-Center Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 03… [cited by applicant]
Liu et al., “CD127 Expression Inversely Correlates with FoxP3 and Suppressive Function of Human CD4+ T reg cells,” The Journal of Experimental Medicine 203(7):1701-1711, 2006. [cited by applicant]
Magenau et al., “Frequency of CD4+CD25hiFOXP3+Regulartory T Cells has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host Disease,” Biol Blood Marrow Transplant 16:907-914, 2010. [cited by applicant]
Martelli et al., “HLA-haploidentical Transplantation with Regulatory and Conventional T-Cell Adoptive Immunotherapy Prevents Acute Leukemia Relapse,” Blood 124(4):638-644, 2014 (8 pages). [cited by applicant]
Montoya et al., “Characterization of Human Invariant Natural Killer T Subsets in Health and Disease using a Novel Invariant Natural Killer T Cell-clonotypic Monoclonal Antibody, 6B11,” Immunology 122:Jan. 14, 2007. [cited by applicant]
Orca Biosystems, Inc., “Methods and Apparatuses for Sorting Targetparticles,” International Application No. PCT/US2017/061414, Filed Nov. 13, 2017, corresponds to U.S. Appl. No. 62/421,979, 146 pages. [cited by applicant]
Patel et al., “Clinical Grade Isolation of Regulatory T Cells from G-CSF Mobilized Peripheral Blood Improves with Initial Depletion of Monocytes,” Am J Blood Res 5(2):79-85, 2015. [cited by applicant]
PCT/US2018/022755 International Search Report and Written Opinion dated Jun. 26, 2018. [cited by applicant]
Peters et al. “Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Tregkk Cryopreservation,” PLoS One 3(9):e3161, 2008 (10 pages). [cited by applicant]
Restifo, “Big Bang Theory of Stem-like T Cells Confirmed,” Blood 124(4):476-477, 2014 (3 pages). [cited by applicant]
Schneidawind et al. “CD4+ Invariant Natural Killer T Cells Protect from Murine GVHD Lethality through Expansion of Donor CD4+CD25+FoxP3+Regulartory T Cells,” Blood 124(22):3320-3328, 2014 (10 pages). [cited by applicant]
Schneidawind et al., “Third-Party CD4+Invariant Natural Killer T Cells Protect from Murine GVHD Lethality,” Blood 125(22):3491-3500, 2015 (11 pages). [cited by applicant]
Seddiki et al., “Expression of Interleukin (IL)-2 and IL-7 Receptors Discriminates Between Human Regulatory and Activated T Cells,” The Journal of Experimental Medicine 203(7):1693-1700, 2006. [cited by applicant]
Stemcell Technologies, “Frequencies of Cell Types in Human Peripheral Blood,” 2017, Version 4.0.0, Document #23629, 1 page. [cited by applicant]
Takahashi et al., “CD4+ T Cells in Aged or Thymectomized Recipients of Allogeneic Stem Cell Transplantations,” Biol Res (2015) 48:41. [cited by applicant]
Taylor et al., “The Infusion of Ex Vivo Activated and Expanded CD4+CD25+Immune Regulatory Cells Inhibits Graft-Versus-Host Disease Lethality,” Blood 99(10):3493-3499, 2002. (8 pages). [cited by applicant]
Tran et al., “Optimized Processing of Growth Factor Mobilized Perpheral Blood CD34+Products by Counterflow Centrifugal Elutriation,” Stem Cells Translational Medicine 1:422-429, 2012. [cited by applicant]
Triplett et al., “Rapid Memory T-Cell Reconstitution Recapitulating CD45RA-depleted haploidentical Transplant Graft Content in Patients with Hematologic Malignancies,” Bone Marrow Transplantation 50:968-977, 2015. [cited by applicant]
Xiong, “Immuno-Magnetic T Cell Depletion for Allogeneic Hematological Stem Cell Transplantation,” doctoral dissertation, The Ohio State University, 2008, 253 pages. [cited by applicant]
U.S. Appl. No. 16/388,095 Notice of Allowance dated Aug. 12, 2020. [cited by applicant]
U.S. Appl. No. 16/388,095 Office Action dated Jan. 13, 2020. [cited by applicant]
EP22152975.3 Extended European Search Report dated Jun. 27, 2022. [cited by applicant]
Karakukcu, M. et al., “Alpha/Beta T Cell Depleted Donor Lymphocyte Infusion,” Database Embase XP055928059, database accession No. EMB-621290086 (2017):86. [cited by applicant]
Zhao, Lei et al., “NKT Cells and Graft-Versus-Host Disease,” Journal of Experimental Hematology, vol. 21, No. 5 (2013), pp. 1345-1350. [cited by applicant]
U.S. Appl. No. 17/091,363, filed Nov. 6, 2020, Ivan K. Dimov. [cited by applicant]
U.S. Appl. No. 16/388,095, filed Apr. 18, 2019, Ivan K. Dimov. [cited by applicant]
U.S. Appl. No. 15/922,709, filed Mar. 15, 2018, Ivan K. Dimov. [cited by applicant]
Anonymous: Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T (RMAT) Designation for Orca-T, Oct. 14, 2020 (Oct. 14, 2020), pp. 1-3, XP093181462, Retrieved from the Internet: URL: htt… [cited by applicant]
Anonymous: Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies, ClinicalTrials.gov, Oct. 5, 2020 (Oct. 5, 2020), pp. 1-8, XP093181451, Retrieved from the Inter… [cited by applicant]
Chinen, T. et al., An essential role for the IL-2 receptor in Treg cell function, Nature Immunology. 2016. 17(11): 1322-1335. [cited by applicant]
Chwojnicki, Kamil et al., Administration of CD4+CD25highCD127-FoxP3+Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study, BIODRUGS, vol. 35, No. 1, Jan. 1, 2021 (Jan. 1, 2021), pp. 47-60, XP093… [cited by applicant]
Database Embase [Online] Jan. 1, 2017 (Jan. 1, 2017), Karakukcu: “Alpha/Beta T cell depleted Donor Lymphocyte Infusion,” XP055928059, Database accession No. EMB-621290086 *abstract*. [cited by applicant]
Di Ianni, M. et al., Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT, International Journal o… [cited by applicant]
Elias, S. and Rudensky, A. Y., Therapeutic use of regulatory T cells for graft-versus-host disease. Br J. Haematol. 2019. 187(1):25-38. [cited by applicant]
Fisher, Sheila A., Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review, British Journal of Hematology, John Wiley, Hoboken, USA,… [cited by applicant]
Hoffman et al., Isolation of CD4∧+CD25∧+Regulatory T Cells for Clinical Trials, Biology of Blood and Marrow Transplantation, Kluge Carden Jennings Publishing, Charlottesville, VA, US, vol. 12, No. 3, Mar. 1, 2006 (Mar. … [cited by applicant]
MACS(C)GMP CD25-PE-Biotin data sheet. Issued Nov. 2018. Retrieved from the internet on Dec. 16, 2025: https:www.miltenyibiotec.com/upload/assets IM0011977.PDF. [cited by applicant]
Mahdi Alahgholi-Hajibehzad et al., Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signalling: 1, 25-Dihydroxyvitamins D3 modulates the suppre… [cited by applicant]
Muffly, L., et al., Safe and effective combination of donor-drived, allogeneic CD19/CD22-CAR T cells with myeloablative graft-engineered allo-HCT for high-risk B-ALL, Blood, Nov. 2024, vol. 144, number supplement 1, pp.… [cited by applicant]
NCT05507827 Safety of myeloablative conditioning, Orca-T, and allogeneic, donor-derived CD19/CD22-CAR (chimeric antigen receptor) T cells in adults with B-cell acute lymphoblastic leukemia (ALL), Aug. 2022 [retrieve fro… [cited by applicant]
Oberg, H.-H. et al. An optimized method for the functional analysis o human regulatory T cells. Scandinavian Journal of Immunology, 2006. 64:353-360. [cited by applicant]
Song, D. et al., Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity, Scientific Reports, vol. 11, No. 1, Jan. 1, 2021, (Jan. 1, 2021), pp. 1-16, XP0932… [cited by applicant]
Spiegel, J.Y. et al., CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial, Nature Medicine, Aug. 2021, vol. 27, No. 8, pp. 1419-1431, doi:… [cited by applicant]
Trzonkowski, P. et al., First-in-man clinical results of the treatment of patients with graft versus hot disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells, Clinical Immunology, Elsevier, Amsterdam, N… [cited by applicant]
Vidal, J.G., et al., 'CD127 is a robust surface marker for the enumeration of natural Treg cells, The FASEB Journal. 2008, vol. 22, No. S1, pp. 848.29. [cited by applicant]